1. Home
  2. MGNX

MGNX

MacroGenics Inc.

Logo MacroGenics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).

Founded: 2000 Country:
United States
United States
Employees: N/A City: Rockville
Market Cap: 1.1B IPO Year: 2013
Target Price: $21.50 AVG Volume (30 days): 1.6M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.15 EPS Growth: N/A
52 Week Low/High: $4.29 - $21.88 Next Earning Date: 05-07-2024
Revenue: $58,749,000 Revenue Growth: -61.33%
Revenue Growth (this year): 15.96% Revenue Growth (next year): 100.18%

Share on Social Networks: